{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:34:56Z","timestamp":1786469696550,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001530","name":"Canterbury Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts. Canterbury had the highest 75 mg use (22.2 vs 1.6\u20137.6 people per 10\u2009000 in the other districts). This relates to differences in local guidelines, therapeutic drug monitoring and availability of clinical pharmacology services. It is unknown if there are differences in patient outcomes.<\/jats:p>","DOI":"10.1111\/imj.70477","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:13:51Z","timestamp":1779725631000},"page":"1433-1437","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geographical variability in dabigatran dosing within New Zealand"],"prefix":"10.1111","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2700-0647","authenticated-orcid":false,"given":"Liam T.","family":"Berryman","sequence":"first","affiliation":[{"name":"Department of Medicine University of Otago  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-5191","authenticated-orcid":false,"given":"Paul K. L.","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago  Christchurch New Zealand"},{"name":"Department of Clinical Pharmacology Health New Zealand  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-4277","authenticated-orcid":false,"given":"Lorna J.","family":"Pairman","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Sundermann","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Doogue","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Otago  Christchurch New Zealand"},{"name":"Department of Clinical Pharmacology Health New Zealand  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"35","article-title":"The changing use of anticoagulants in New Zealand","volume":"135","author":"Harper P","year":"2022","journal-title":"N Z Med J"},{"key":"e_1_2_5_3_1","volume-title":"Pradaxa","author":"New Zealand Medicines and Medical Devices Safety Authority","year":"2024"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12364"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.104"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2927"},{"key":"e_1_2_5_7_1","volume-title":"Anticoagulant Stewardship Programme Summary Report","author":"Health Quality & Safety Commission New Zealand","year":"2024"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000713"},{"key":"e_1_2_5_9_1","volume-title":"Dabigatran and Rivaroxaban","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_10_1","volume-title":"Dabigatran and rivaroxaban","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_11_1","volume-title":"Dabigatran and rivaroxaban","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_12_1","volume-title":"Direct Oral Anticoagulants","author":"Community HealthPathways","year":"2025"},{"key":"e_1_2_5_13_1","first-page":"2025","volume-title":"Deep Vein Thrombosis (DVT)","author":"Community HealthPathways"},{"key":"e_1_2_5_14_1","volume-title":"Dabigatran and Rivaroxaban","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_15_1","volume-title":"Anticoagulation Therapy for AF and VTE","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_16_1","volume-title":"Direct Oral Anticoagulant","author":"Community HealthPathways","year":"2021"},{"key":"e_1_2_5_17_1","volume-title":"Dabigatran and Rivaroxaban","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_18_1","volume-title":"Anticoagulation","author":"Community HealthPathways","year":"2023"},{"key":"e_1_2_5_19_1","volume-title":"Dabigatran Etexilate","author":"New Zealand Formulary","year":"2025"},{"key":"e_1_2_5_20_1","volume-title":"Pharmaceutical Data Web Tool","author":"Health New Zealand","year":"2024"},{"key":"e_1_2_5_21_1","volume-title":"Subnational Population Estimates (DHB) 2019\u20132023 (2015 Boundaries)","author":"Stats NZ","year":"2018"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.70477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:42:36Z","timestamp":1786466556000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/imj.70477"],"URL":"https:\/\/doi.org\/10.1111\/imj.70477","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}